Brind.

Dexcom executives, including Jeff Johnson, faced questioning from analysts like UBS and Raymond James regarding gross margins, international performance in markets like France and Japan, and resilience during a downturn.

1 report, 0 independent Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Dexcom executives, including Jeff Johnson, faced questioning from analysts like UBS and Raymond James regarding gross margins, international performance in markets like France and Japan, and resilience during a downturn.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet